Mease, Philip J. http://orcid.org/0000-0002-6620-0457
Kellner, Herbert
Morita, Akimichi
Kivitz, Alan J.
Aslanyan, Stella
Padula, Steven J.
Topp, Andrew S.
Eldred, Ann
Behrens, Frank
Papp, Kim A.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial
https://doi.org/10.1007/s40744-022-00474-5
OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial
https://doi.org/10.1136/annrheumdis-2018-eular.2140
Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
https://doi.org/10.1007/s40744-022-00495-0
Documents that mention this clinical trial
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial
https://doi.org/10.1007/s40744-022-00474-5
Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
https://doi.org/10.1007/s40744-022-00495-0
Funding for this research was provided by:
AbbVie
Boehringer Ingelheim
Article History
Received: 27 April 2022
Accepted: 21 June 2022
First Online: 5 August 2022